As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.
17 Analysts have issued a Y-mAbs Therapeutics, Inc. forecast:
17 Analysts have issued a Y-mAbs Therapeutics, Inc. forecast:
Jun '25 |
+/-
%
|
||
Revenue | 85 85 |
1%
1%
|
|
Gross Profit | 70 70 |
9%
9%
|
|
EBITDA | -26 -26 |
3%
3%
|
EBIT (Operating Income) EBIT | -27 -27 |
4%
4%
|
Net Profit | -22 -22 |
10%
10%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Head office | United States |
CEO | Michael Rossi |
Employees | 104 |
Founded | 2015 |
Website | www.ymabs.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.